Skip to main content
News Ulas 10.2019
During tumor development, macrophages (brown), the scavengers of the immune system, migrate into the diseased tissue (cancer cells: blue) without destroying it.
© Karin E. de Visser / the Netherlands Cancer Institute

Publication

New method identifies aggressive breast cancer

Aggressive forms of breast cancer often manipulate the immune response in their favor. This manipulation is revealed in humans by the same immunological "signature" as in mice. This is shown by a study carried out by scientists from the University of Bonn and memebers of the Cluster of Excellence ImmunoSensation together with Dutch colleagues. Their method makes it possible to obtain an indication of the prognosis of the disease using patients' tumor tissue. The results are published in the journal "Cell Reports".


Publication

Sander Tuit, Camilla Salvagno, Theodore S. Kapellos, Cheei-Sing Hau, Lea Seep, Marie Oestreich, Kathrin Klee, Karin E. de Visser, Thomas Ulas und Joachim L. Schultze: Transcriptional signature derived from murine tumor-associated macrophages correlates with poor outcome in breast cancer patients. Cell Reports; DOI: 10.1016/j.celrep.2019.09.067

Contact

Dr. Thomas Ulas

Head of the Bioinformatics Working Group

LIMES-Institute

University of Bonn

Tel. +49-228-7362722

E-mail: t.ulas@uni-bonn.de

Related news

Tracking glioblastoma cell spread in human brain tissue

Publication

Core2Edge: How tumor cells conquer the brain

—Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

Publication

Approval of a Novel Retinal Implant Technology

—A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

Publication

The Gut as a Key Player in Immunotherapy for MS

—B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry

Back to the news overview